par Devogelaer, J.-P.;Brown, Jacques;Burckhardt, Peter;Meunier, Pierre J.;Goemaere, Stefan;Lippuner, Kurt;Body, Jean-Jacques ;Samsioe, Göran;Felsenberg, Dieter;Fashola, Taiwo;Sanna, Liuska;Ortmann, C.E.;Trechsel, Ulrich;Krasnow, Joel;Eriksen, Erik Fink;Garnero, Patrick
Référence Osteoporosis international, 18, 9, page (1211-1218)
Publication Publié, 2007-09
Référence Osteoporosis international, 18, 9, page (1211-1218)
Publication Publié, 2007-09
Article révisé par les pairs
Résumé : | In a 5-year study involving 119 postmenopausal women, zoledronic acid 4 mg given once-yearly for 2, 3 or 5 years was well tolerated with no evidence of excessive bone turnover reduction or any safety signals. BMD increased significantly. Bone turnover markers decreased from baseline and were maintained within premenopausal reference ranges. |